RNA vaccine study for newly diagnosed adult and pediatric brain tumors
Part of Blood & lymphatic, Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This Phase 1 trial studies an “RNA-lipid particle” vaccine given after surgery for certain newly diagnosed brain cancers (glioblastoma in adults, high-grade glioma in children/teens). The goal is to see whether the vaccine is safe and can train the immune system to fight the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be in the right age group: adults 21+, or children/teens over 3 up to 25.
- Have a newly diagnosed brain tumor confirmed by biopsy (not a regrowth tumor).
- Tumor must meet specific tumor features: for adult glioblastoma, it must be MGMT low or unmethylated; not secondary glioblastoma.
- After surgery, the remaining tumor on MRI must be 3 cm or smaller (and scans must be done before and within a week after surgery).
- Be well enough to recover from surgery and complications, and be stable for at least 1 week if you have any neurologic deficits.
- Agree to take an anti-seizure medicine (like levetiracetam) during vaccinations and follow pregnancy-prevention rules if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a virus called DNX-2401, which is injected directly into the tumor, for children and young adults with high-grade brain tumors that have come back or are hard to treat. The goal is to see if this virus can shrink or control the tumor.
This trial tests a vaccine that may help the immune system fight brain tumors (medulloblastoma, high-grade glioma, and DIPG). It is for patients who have already had standard treatment and whose tumors are still present or have returned.
This trial tests a two-part treatment: an injected virus (DB107-RRV) plus an oral medication (DB107-FC) for people whose high-grade glioma (a type of brain tumor) has come back. The virus is designed to deliver a gene that makes the tumor sensitive to the oral drug, which then helps kill the cancer cells.
This trial is testing a new immunotherapy (nivolumab) for children, teens, and young adults with a specific type of aggressive brain tumor (glioblastoma that has a DNA repair problem). It aims to see if giving this treatment early, right after surgery, can help the immune system fight the tumor.
This trial tests a new treatment that combines a specially designed virus to attack tumor cells with an immunotherapy drug to help the immune system fight the cancer. It is for people whose high-grade glioma (a type of brain tumor) has come back after standard treatment.
This trial tests a new mRNA vaccine for people with a type of brain tumor called high-grade glioma that has come back or progressed. The vaccine is designed to help your immune system recognize and attack the tumor cells.
Hear when a new High Grade Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.